Header Logo

Connection

JOHN KIRKWOOD to Prognosis

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Prognosis.
JOHN KIRKWOOD
Connection Strength
2.153
Prognosis
  1. Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. Clin Cancer Res. 2025 Aug 01; 31(15):3249-3258.
    View in: PubMed
    Score: 0.121
  2. Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas. J Immunother Cancer. 2024 Nov 12; 12(11).
    View in: PubMed
    Score: 0.115
  3. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol. 2023 05 01; 159(5):545-553.
    View in: PubMed
    Score: 0.103
  4. Poorer survival outcomes in patients with multiple versus single primary melanoma. Cancer. 2022 06 01; 128(11):2098-2106.
    View in: PubMed
    Score: 0.096
  5. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. Cancer. 2019 09 01; 125(17):3013-3024.
    View in: PubMed
    Score: 0.078
  6. Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
    View in: PubMed
    Score: 0.078
  7. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017 Nov 15; 23(22):6888-6892.
    View in: PubMed
    Score: 0.069
  8. Downstream consequences of melanoma screening in a community practice setting: First results. Cancer. 2016 Oct 15; 122(20):3152-3156.
    View in: PubMed
    Score: 0.064
  9. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol. 2015 Dec 01; 33(34):4066-76.
    View in: PubMed
    Score: 0.061
  10. State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am. 2014 Jun; 28(3):415-35.
    View in: PubMed
    Score: 0.056
  11. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res. 2014 Apr; 24(2):150-7.
    View in: PubMed
    Score: 0.055
  12. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705.
    View in: PubMed
    Score: 0.054
  13. A four-marker signature of TNF-RII, TGF-a, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014 Jan 23; 12:19.
    View in: PubMed
    Score: 0.054
  14. Advances in adjuvant therapy: potential for prognostic and predictive biomarkers. Methods Mol Biol. 2014; 1102:45-69.
    View in: PubMed
    Score: 0.054
  15. Pediatric melanoma: analysis of an international registry. Cancer. 2013 Nov 15; 119(22):4012-9.
    View in: PubMed
    Score: 0.053
  16. Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis. 2012 Oct; 29(7):775-96.
    View in: PubMed
    Score: 0.049
  17. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol. 2011 Jul; 33(4):385-91.
    View in: PubMed
    Score: 0.044
  18. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010 Apr; 133(4):646-53.
    View in: PubMed
    Score: 0.042
  19. Predictors of response to interferon therapy. Curr Opin Oncol. 2009 Mar; 21(2):138-43.
    View in: PubMed
    Score: 0.039
  20. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009 Jan 01; 27(1):38-44.
    View in: PubMed
    Score: 0.038
  21. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008 Jul 10; 26(20):3445-55.
    View in: PubMed
    Score: 0.037
  22. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb 01; 26(4):527-34.
    View in: PubMed
    Score: 0.036
  23. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16; 354(7):709-18.
    View in: PubMed
    Score: 0.031
  24. Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma? Nat Clin Pract Oncol. 2005 May; 2(5):240-1.
    View in: PubMed
    Score: 0.030
  25. Melanoma in the older person. Oncology (Williston Park). 2004 Aug; 18(9):1187-96; discussion 1196-7.
    View in: PubMed
    Score: 0.028
  26. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004 Mar 01; 10(5):1670-7.
    View in: PubMed
    Score: 0.027
  27. Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts. Cancer Med. 2023 12; 12(24):22103-22108.
    View in: PubMed
    Score: 0.027
  28. Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes. Front Immunol. 2023; 14:1171978.
    View in: PubMed
    Score: 0.026
  29. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol. 2022 11 10; 40(32):3741-3749.
    View in: PubMed
    Score: 0.024
  30. Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. Ann Surg Oncol. 2022 Sep; 29(9):5948-5956.
    View in: PubMed
    Score: 0.024
  31. An update on adjuvant interferon for melanoma. Cancer Control. 2002 Jan-Feb; 9(1):16-21.
    View in: PubMed
    Score: 0.024
  32. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000 Nov 15; 18(22):3782-93.
    View in: PubMed
    Score: 0.022
  33. Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res. 2020 12; 8(12):1554-1567.
    View in: PubMed
    Score: 0.022
  34. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020 11; 9(22):8650-8661.
    View in: PubMed
    Score: 0.022
  35. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 09 01; 156(9):1004-1011.
    View in: PubMed
    Score: 0.021
  36. Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma. Oncologist. 2020 08; 25(8):e1209-e1220.
    View in: PubMed
    Score: 0.021
  37. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 03; 21(3):358-372.
    View in: PubMed
    Score: 0.021
  38. A Th1/IFN? Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 04 01; 26(7):1725-1735.
    View in: PubMed
    Score: 0.020
  39. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2019 12 10; 37(35):3350-3358.
    View in: PubMed
    Score: 0.020
  40. Adjuvant IFN alpha2 therapy of melanoma. Lancet. 1998 Jun 27; 351(9120):1901-3.
    View in: PubMed
    Score: 0.018
  41. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 07; 19(7):916-929.
    View in: PubMed
    Score: 0.018
  42. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017 Dec 01; 35(34):3815-3822.
    View in: PubMed
    Score: 0.017
  43. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017; 5:44.
    View in: PubMed
    Score: 0.017
  44. Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery. J Neurosurg. 2018 01; 128(1):14-22.
    View in: PubMed
    Score: 0.017
  45. Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol. 2016 Jan; 136(1):339-342.
    View in: PubMed
    Score: 0.016
  46. Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy. Melanoma Res. 2014 Oct; 24(5):437-47.
    View in: PubMed
    Score: 0.014
  47. Does metastasectomy improve survival in skeletal melanoma? Melanoma Res. 2014 Aug; 24(4):354-9.
    View in: PubMed
    Score: 0.014
  48. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014 Jun 15; 20(12):3310-8.
    View in: PubMed
    Score: 0.014
  49. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37.
    View in: PubMed
    Score: 0.014
  50. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.
    View in: PubMed
    Score: 0.014
  51. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8.
    View in: PubMed
    Score: 0.013
  52. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer. 2013 Aug 01; 119(15):2737-46.
    View in: PubMed
    Score: 0.013
  53. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One. 2012; 7(7):e40805.
    View in: PubMed
    Score: 0.012
  54. Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. J Transl Med. 2011 May 26; 9:78.
    View in: PubMed
    Score: 0.011
  55. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer. 2010 Sep 15; 116(18):4326-33.
    View in: PubMed
    Score: 0.011
  56. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg. 2011 Mar; 114(3):769-79.
    View in: PubMed
    Score: 0.011
  57. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.
    View in: PubMed
    Score: 0.010
  58. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosom Med. 1990 Jan-Feb; 52(1):73-85.
    View in: PubMed
    Score: 0.010
  59. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007 Apr 15; 13(8):2422-8.
    View in: PubMed
    Score: 0.008
  60. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007 Mar; 60(3):471-81; discussion 481-2.
    View in: PubMed
    Score: 0.008
  61. Prognostic role of antibody reactivity to melanoma. J Clin Invest. 1986 Apr; 77(4):1116-21.
    View in: PubMed
    Score: 0.008
  62. Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. Melanoma Res. 2006 Apr; 16(2):165-74.
    View in: PubMed
    Score: 0.008
  63. Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer. 2005 Dec 15; 104(12):2784-91.
    View in: PubMed
    Score: 0.008
  64. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol. 2004 Jan 01; 22(1):11-4.
    View in: PubMed
    Score: 0.007
  65. Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER). Cancer. 1982 Oct 01; 50(7):1299-303.
    View in: PubMed
    Score: 0.006
  66. Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen. Cancer. 1981 May 15; 47(10):2414-21.
    View in: PubMed
    Score: 0.006
  67. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000 Mar 15; 88(6):1484-91.
    View in: PubMed
    Score: 0.005
  68. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):581-9.
    View in: PubMed
    Score: 0.005
  69. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1997 Jun; 20(3):251-3.
    View in: PubMed
    Score: 0.004
  70. Recent advances in the care of the patient with malignant melanoma. Ann Surg. 1997 Jan; 225(1):1-14.
    View in: PubMed
    Score: 0.004
  71. Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev. 1984 Mar; 11(1):1-26.
    View in: PubMed
    Score: 0.002
  72. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983 Nov; 9(5):689-96.
    View in: PubMed
    Score: 0.002
  73. High-dose fraction radiation therapy for intracranial metastases of malignant melanoma: a comparison with low-dose fraction therapy. Cancer. 1982 Jun 01; 49(11):2289-94.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.